FundedIQ
Biotechnology

Protoga

Protoga is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.

www.protogabio.com Shenzhen, China 1-10 employees
Total raised
$14.8M
Rounds
1
Latest
Series A
Aug 2026

Protoga is a biotech firm that focused on the development of innovative microalgae biosynthesis technology.

Protoga has raised $14.8M across 1 round. Its most recent round was a Series A of $14.8M in Aug 2026. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Aug 3, 2026
Series A
$14.8M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Protoga is featured in

Similar companies

Yuantian Bio

Yuantian Bio is a biotechnology company specializing in enzymatic regeneration and commercial plastic PET applications.

Series A $14.8M
NewLine

NewLine researches phage feed additives to prevent livestock infections.

Series A $14.8M
Enze Kangtai

Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research.

Series B $14.0M
Salus BioMed

Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products.

Series B $7.0M
Epigenic Therapeutics

Epigenic Therapeutics is a drug development company that develops gene modulation therapies through the regulation of epigenetic mechanisms.

Series B $60.0M
CANbridge Pharmaceuticals

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

$43.0M
Harbour Biomed

Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.

$103M
JW Therapeutics

JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.

$100M
LifeMine Therapeutics

LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.

Series E $188M
Metaphore Biotechnologies

Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore is dedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect.

Series Unknown
BRAINBox Solutions

BRAINBox provides objective evidence of injury and prediction of patient recovery. BRAINBox Solutions' multi-modality approach is led by the leaders in the industry. It includes blood biomarker panels available on a point of care instrument and standard laboratory systems.

Series Unknown
CND Life Sciences

CND Life Sciences is committed to supporting patients with neurodegenerative diseases, offering the Syn-One Test® as a first-of-its-kind tool to detect and measure misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers. This test helps confirm synucleinopathies like Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure. The company operates a CLIA-certified and CAP-accredited lab in Scottsdale, AZ, providing a convenient and accurate alternative for diagnosis through skin biopsies. Additionally, CND collaborates with biopharmaceutical companies to advance research in the field.

Private Equity
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.